Logo

Xerion Pharmaceuticals Licenses Antibody Library from Cambridge Antibody Technology

Jun 05, 2001

NEW YORK, June 5 - Xerion Pharmaceuticals has agreed to license Cambridge Antibody Technology's library of human phage antibodies for use in drug discovery and functional proteomics, the companies said Tuesday. 

Xerion, based in Martinsried, Germany, will pay CAT an undisclosed license fee for the technology. No other financial details were available. 

"CAT's antibody competence and Xerion's XCALIbur technologies will complement each other exceptionally well and thus create powerful target validation tools," Markus Ewert, CEO of Xerion, said in a statement.

In March, Xerion raised $11.1 million euros ($9.4 million) in a second round private placement, and hired Markus Ewert as CEO from Axxima Pharmaceuticals, another Martinsried-based pharmacueutical company.

CAT, in Cambridge, UK, has licensed its antibody library to a number of pharmaceutical and biotechnology companies, including Genentech, Pfizer, and Immunex.

 
Breaking News
The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.